Tag Archives: GILD

Hot Heal Care Stocks To Own For 2019

Facing more than $80,000 in student loan debt, Tiffany Tatafu did what thousands of other student loan borrowers do: She searched for answers on her phone.

The single mother of two had heard that as a public employee, she could be eligible for student loan forgiveness. She’d landed a job as a student support coordinator at Arizona State University after earning a master’s degree in education in 2017.

Tatafu called one of the first listings that came up in her search.

A representative at the company pushed her to sign up for its service, which cost $50 per month for three years on top of her normal student loan payments. They told her it was the only way she’d qualify for forgiveness, Tatafu recalls.

“They definitely made it sound like I had to go through them or I would not be in the program,” Tatafu says. “So they lied.”

Hot Heal Care Stocks To Own For 2019: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Lee Jackson]

    This stock is trading a very reasonable 10.6 times estimated 2018 earnings. Gilead Sciences Inc. (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes therapies for the treatment of HIV/AIDS, liver disease, cancer and inflammation. The recent acquisition of KITE allows for entry into the CAR-T space, indicating a renewed focus in oncology.

  • [By Todd Campbell, Keith Speights, and Chuck Saletta]

    It’s not every day that shares in top companies can be bought at a reasonable valuation, so investors ought to pay attention when it happens. For instance, these three Motley Fool contributors believe Gilead Sciences (NASDAQ:GILD), Magellan Health (NASDAQ:MGLN), and Celgene Corp (NASDAQ:CELG) shares represent a unique opportunity to buy leading healthcare companies on sale. Are these stocks a good fit for your portfolio?

  • [By Keith Speights]

    You might be tempted to write off Gilead Sciences (NASDAQ:GILD).

    The once high-flying biotech has lost 45% of its market cap since mid-2015. After the stock climbed more than 20% earlier this year, Gilead lost all of those gains and then some. Sales for the company’s hepatitis C virus (HCV) franchise continue to drop faster than a brick. Gilead’s other drugs can’t generate nearly enough growth to offset the HCV declines.

Hot Heal Care Stocks To Own For 2019: Dynamic Materials Corporation(BOOM)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Dmc Global (NASDAQ:BOOM) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Thursday.

  • [By Joseph Griffin]

    Dmc Global (NASDAQ:BOOM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “DMC Global Inc. is a technology company. Its operating sector consists of industrial infrastructure and oilfield products and services. Industrial infrastructure sector is served by DMC’s NobelClad business is a manufacturer of explosion-welded clad metal plates, which are used to fabricate capital equipment. Oilfield products and services sector is served by DynaEnergetics, is a developer, manufacturer and marketer of advanced explosive components and systems used to perforate oil and gas wells. DMC Global Inc. is based in Boulder, Colorado. “

  • [By Motley Fool Transcribers]

    DMC Global Inc.  (NASDAQ:BOOM)Q4 2018 Earnings Conference CallFeb. 21, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Hot Heal Care Stocks To Own For 2019: CB Financial Services, Inc.(CBFV)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on CB Financial Services (CBFV)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    CB Financial Services Inc (NASDAQ:CBFV)’s share price hit a new 52-week high and low on Wednesday following a dividend announcement from the company. The company traded as low as $34.95 and last traded at $34.40, with a volume of 4600 shares traded. The stock had previously closed at $34.65.

Top Warren Buffett Stocks To Buy Right Now

Investors looking for profits in the healthcare sector had a difficult time in 2017 if they weren’t in biotech. The Health Care SPDR ETF (NYSE: XLV) only gained 13.15% last year, while the S&P 500 climbed 22.5% over the same time period.

But the biotech sector crushed the market, with the SPDR S&P Biotech ETF (NYSE: XBI) returning a market-beating 43.36% in 2017, nearly double the broader S&P 500.

That’s why we’ll show you the three best biotech stocks to buy for 2018.

Despite the exceptional run for biotech stocks in 2017, the broader healthcare sector has been facing a strong headwind over the past few years that scared away some investors.

Drug pricing controversies, increased generic competition for blockbuster drugs, and the recent merger between retail giant CVS Health Corp. (NYSE: CVS) and insurance company Aetna Inc. (NYSE: AET) have weakened returns for shareholders.
In addition, Amazon.com Inc. (Nasdaq: AMZN), Warren Buffett’s Berkshire Hathaway Inc. (NYSE: BRK.A), and JPMorgan Chase & Co. (NYSE: JPM) announced a joint venture to enter the health insurance industry.

Top Warren Buffett Stocks To Buy Right Now: Castle Brands, Inc.(ROX)

Advisors’ Opinion:

  • [By Logan Wallace]

    Castle Brands (NYSEAMERICAN:ROX) was the recipient of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 6,422,984 shares, a decrease of 5.8% from the April 30th total of 6,815,151 shares. Based on an average daily volume of 169,266 shares, the short-interest ratio is presently 37.9 days. Currently, 7.2% of the company’s stock are sold short.

Top Warren Buffett Stocks To Buy Right Now: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By George Budwell]

    When it comes to biotech stocks, Celgene (NASDAQ:CELG) and Gilead Sciences (NASDAQ:GILD) are easily two of the brightest stars. After all, these two top dogs have generated enormous returns for investors since the start of the biotech bull market back in 2010:

  • [By Keith Speights]

    Gilead Sciences (NASDAQ:GILD), Amgen (NASDAQ:AMGN), and Johnson & Johnson (NYSE:JNJ) rank as the three top biopharmaceutical companies when it comes to cash stockpiles. Here’s what these drugmakers are most likely to do with all that money — and whether or not you should consider investing some of your hard-earned cash to buy their stocks.

  • [By Cory Renauer]

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL), and Gilead Sciences Inc. (NASDAQ:GILD) are three top stocks for investing this arena, which could be worth as much as $35 billion annually by 2020. There are plenty of companies with NASH candidates, but these three biotechs rise to the top of the list for some very different reasons.

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB), Celgene Corporation (NASDAQ:CELG), and Gilead Sciences Inc. (NASDAQ:GILD) around this time in 1998 would have made you a millionaire already. 

  • [By Chris Lange]

    Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest increase slightly to 16.28 million shares from 16.13 million in the previous period. Shares were trading at $67.85, in a 52-week range of $63.76 to $89.54.

  • [By Chris Lange]

    Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest decrease to 17.44 million shares from 18.22 million in the previous period. Shares were trading at $72.72, in a 52-week range of $63.76 to $89.54.

Top Warren Buffett Stocks To Buy Right Now: Ducommun Incorporated(DCO)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Companies Reporting After The Bell
    NVIDIA Corporation (NASDAQ: NVDA) is estimated to post quarterly earnings at $1.45 per share on revenue of $2.89 billion.
    News Corporation (NASDAQ: NWSA) is projected to post quarterly earnings at $0.07 per share on revenue of $1.99 billion.
    Symantec Corporation (NASDAQ: SYMC) is estimated to post quarterly earnings at $0.39 per share on revenue of $1.19 billion.
    Pilgrim's Pride Corporation (NASDAQ: PPC) is projected to post quarterly earnings at $0.54 per share on revenue of $2.65 billion.
    Hawaiian Electric Industries, Inc. (NYSE: HE) is expected to post quarterly earnings at $0.38 per share on revenue of $556.81 million.
    Air Lease Corporation (NYSE: AL) is estimated to post quarterly earnings at $1.01 per share on revenue of $383.37 million.
    Flowserve Corporation (NYSE: FLS) is expected to post quarterly earnings at $0.27 per share on revenue of $880.89 million.
    Civitas Solutions, Inc. (NYSE: CIVI) is projected to post quarterly earnings at $0.12 per share on revenue of $396.25 million.
    The Trade Desk, Inc. (NASDAQ: TTD) is estimated to post quarterly earnings at $0.1 per share on revenue of $73.23 million.
    Amdocs Limited (NYSE: DOX) is projected to post quarterly earnings at $0.95 per share on revenue of $980.50 million.
    Yelp Inc. (NYSE: YELP) is estimated to post quarterly loss at $0.04 per share on revenue of $220.14 million.
    Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) is expected to post quarterly earnings at $0.43 per share on revenue of $210.01 million.
    TiVo Corporation (NASDAQ: TIVO) is projected to post quarterly earnings at $0.37 per share on revenue of $198.62 million.
    Ritchie Bros. Auctioneers Incorporated (NYSE: RBA) is expected to post quarterly earnings at $0.17 per share on revenue of $153.87 million.
    Uniti Group Inc. (NASDAQ: UNIT) is estimated to post quarterly earnings at $0.01 per share on revenue of $247.16 million.
    Jagged Peak En

  • [By Stephan Byrd]

    Ducommun (NYSE:DCO) had its price target increased by Canaccord Genuity from $36.00 to $38.00. The firm currently has a buy rating on the stock.

    Fortress Biotech (NASDAQ:FBIO) was given a $11.00 target price by analysts at HC Wainwright. The firm currently has a buy rating on the stock.

  • [By Ethan Ryder]

    Astronics (NASDAQ: ATRO) and Ducommun (NYSE:DCO) are both small-cap aerospace companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

  • [By Stephan Byrd]

    Astronics (NASDAQ: ATRO) and Ducommun (NYSE:DCO) are both small-cap aerospace companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.

Top Warren Buffett Stocks To Buy Right Now: Chipotle Mexican Grill Inc.(CMG)

Advisors’ Opinion:

  • [By Daniel B. Kline]

    I like Chipotle Mexican Grill (NYSE:CMG), both as a business and as a consumer who enjoys tacos. The company has figured out how to create great-tasting fast food made from recognizable ingredients at a decent price.

  • [By ]

    Chipotle Mexican Grill Inc. (CMG) investors are having a very good day. 

    The stock is up 24% Thursday, April 26, following a redemptive first-quarter earnings release under brand-new CEO Brian Niccol. As of 3pm, the stock was trading at $422.70.

  • [By Jon C. Ogg]

    The long saga of the Chipotle Mexican Grill Inc. (NYSE: CMG) and its food fiascos finally may have seen its worst. In fact, an almost 20% gain in the shares after the earnings report may be signaling something even larger. Chipotle shares have now rallied a whopping 60% from the post-panic lows, and many analysts on Wall Street are still hanging on to a very cautious or negative stance.

Top Warren Buffett Stocks To Buy Right Now: Celanese Corporation(CE)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Celanese (NYSE:CE)‘s stock had its “outperform” rating reiterated by Cowen in a report issued on Friday. They presently have a $125.00 price objective on the basic materials company’s stock, up from their previous price objective of $120.00. Cowen’s price objective would suggest a potential upside of 15.06% from the company’s previous close.

  • [By ]

    Eli Lilly announced in October it was conducting a strategic review for the unit.  Elanco on Monday said it has appointed Christopher Jensen, who was most recently with Celanese Corp. (CE) , as chief financial officer.

  • [By Max Byerly]

    Loomis Sayles & Co. L P purchased a new position in Celanese Co. (NYSE:CE) during the 1st quarter, HoldingsChannel reports. The firm purchased 101,256 shares of the basic materials company’s stock, valued at approximately $10,147,000.

  • [By Ethan Ryder]

    Jennison Associates LLC trimmed its stake in shares of Celanese Co. (NYSE:CE) by 0.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 527,082 shares of the basic materials company’s stock after selling 3,006 shares during the period. Jennison Associates LLC’s holdings in Celanese were worth $58,538,000 as of its most recent SEC filing.

  • [By Shane Hupp]

    Celanese (NYSE: CE) and Sealed Air (NYSE:SEE) are both basic materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Top 5 Heal Care Stocks To Invest In 2019

Public Employees Retirement Association of Colorado trimmed its position in shares of Chimera Investment Co. (NYSE:CIM) by 18.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 51,307 shares of the real estate investment trust’s stock after selling 11,267 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Chimera Investment were worth $893,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CIM. American Century Companies Inc. purchased a new position in Chimera Investment during the 4th quarter worth approximately $9,021,000. Two Sigma Investments LP grew its position in Chimera Investment by 916.1% during the 4th quarter. Two Sigma Investments LP now owns 420,558 shares of the real estate investment trust’s stock worth $7,772,000 after purchasing an additional 379,167 shares in the last quarter. Wells Fargo & Company MN grew its position in Chimera Investment by 19.2% during the 1st quarter. Wells Fargo & Company MN now owns 1,300,895 shares of the real estate investment trust’s stock worth $22,648,000 after purchasing an additional 209,573 shares in the last quarter. EnTrustPermal Partners Offshore LP purchased a new position in Chimera Investment during the 4th quarter worth approximately $2,938,000. Finally, Mackenzie Financial Corp grew its position in Chimera Investment by 342.5% during the 4th quarter. Mackenzie Financial Corp now owns 197,359 shares of the real estate investment trust’s stock worth $3,647,000 after purchasing an additional 152,755 shares in the last quarter. Hedge funds and other institutional investors own 51.41% of the company’s stock.

Top 5 Heal Care Stocks To Invest In 2019: Reliance Steel & Aluminum Co.(RS)

Advisors’ Opinion:

  • [By Max Byerly]

    Deroy & Devereaux Private Investment Counsel Inc. raised its holdings in Reliance Steel & Aluminum Co (NYSE:RS) by 0.4% during the 2nd quarter, HoldingsChannel reports. The fund owned 229,801 shares of the industrial products company’s stock after acquiring an additional 848 shares during the quarter. Reliance Steel & Aluminum accounts for approximately 2.1% of Deroy & Devereaux Private Investment Counsel Inc.’s investment portfolio, making the stock its 11th largest holding. Deroy & Devereaux Private Investment Counsel Inc.’s holdings in Reliance Steel & Aluminum were worth $20,117,000 as of its most recent SEC filing.

  • [By Joseph Griffin]

    American Century Companies Inc. grew its stake in Reliance Steel & Aluminum Co (NYSE:RS) by 2.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,780 shares of the industrial products company’s stock after acquiring an additional 748 shares during the period. American Century Companies Inc.’s holdings in Reliance Steel & Aluminum were worth $2,725,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    ValuEngine cut shares of Reliance Steel & Aluminum (NYSE:RS) from a buy rating to a hold rating in a research note published on Wednesday.

    Other analysts have also issued reports about the stock. KeyCorp boosted their target price on shares of Reliance Steel & Aluminum from $95.00 to $97.00 and gave the company an overweight rating in a research report on Thursday, February 15th. Zacks Investment Research lowered shares of Reliance Steel & Aluminum from a buy rating to a hold rating in a research report on Tuesday, March 13th. Cowen boosted their target price on shares of Reliance Steel & Aluminum from $101.00 to $107.00 and gave the company an outperform rating in a research report on Friday, February 16th. Goldman Sachs assumed coverage on shares of Reliance Steel & Aluminum in a research report on Tuesday, March 20th. They set a neutral rating and a $103.00 target price for the company. Finally, Bank of America set a $97.00 target price on shares of Reliance Steel & Aluminum and gave the company a buy rating in a research report on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $96.71.

  • [By Shane Hupp]

    Reliance Steel & Aluminum Co (NYSE:RS) hit a new 52-week high and low on Thursday . The company traded as low as $97.41 and last traded at $94.18, with a volume of 15817 shares trading hands. The stock had previously closed at $96.27.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Reliance Steel & Aluminum (RS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lee Jackson]

    Reliance Steel & Aluminum
    This is a top steel services play that the Deutsche Bank team is very positive on. Reliance Steel & Aluminum Co. (NYSE: RS) provides metals processing services and distributes a line of about 100,000 metal products, including alloy, aluminum, brass, copper, carbon steel, stainless steel, titanium and specialty steel products. Its primary processing services comprise cutting, leveling, sawing, machining and electropolishing.

Top 5 Heal Care Stocks To Invest In 2019: Provident Financial Holdings, Inc.(PROV)

Advisors’ Opinion:

  • [By Max Byerly]

    News articles about Provident Financial (NASDAQ:PROV) have been trending somewhat negative this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Provident Financial earned a daily sentiment score of -0.02 on Accern’s scale. Accern also assigned news articles about the financial services provider an impact score of 45.9215692366566 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

  • [By Ethan Ryder]

    E*TRADE Financial (NASDAQ: ETFC) and Provident Financial (NASDAQ:PROV) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

  • [By Logan Wallace]

    Charter Financial (NASDAQ: CHFN) and Provident Financial (NASDAQ:PROV) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Top 5 Heal Care Stocks To Invest In 2019: Canadian Solar Inc.(CSIQ)

Advisors’ Opinion:

  • [By Logan Wallace]

    Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

    Get Canadian Solar alerts:

    Contrasting Canadian Solar (CSIQ) & NVE (NVEC) (americanbankingnews.com) Africa: Canadian Solar Partners With ET Energy to Build 132 MWP of Solar Projects in South Africa (allafrica.com) Canadian Solar Partners with ET Energy to Build 132 MWp of Solar Projects in South Africa (finance.yahoo.com) Canadian Solar Inc (CSIQ) Trend Analysis Report (emnnews.com) Canadian Solar Inc. (NasdaqGS:CSIQ) Quant Update and Deep Dive into the 0.023549 ROA (baycityobserver.com)

    A number of brokerages have issued reports on CSIQ. B. Riley reduced their price objective on shares of Canadian Solar from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Thursday, August 23rd. Zacks Investment Research downgraded shares of Canadian Solar from a “buy” rating to a “hold” rating in a research report on Friday, August 17th. BidaskClub downgraded shares of Canadian Solar from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. ValuEngine downgraded shares of Canadian Solar from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 20th. Finally, JPMorgan Chase & Co. raised shares of Canadian Solar from an “underweight” rating to a “neutral” rating and reduced their price objective for the stock from $17.00 to $15.00 in a research report on Thursday, June 7th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company. Canadian Solar has an average rating of “Hold” and a consensus price target of $17.67.

  • [By Motley Fool Staff]

    Canadian Solar (NASDAQ:CSIQ) Q1 2018 Earnings Conference CallMay. 16, 2018 8:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Paul Ausick]

    Canadian Solar Inc. (NASDAQ: CSIQ) saw an increase of 3.1% in short interest during the first two weeks of August. Some 7.6% of the total float, or 3.4 million shares, were short and days to cover fell from five to four. The company’s share price traded flat over the two-week period and shares closed Friday at $13.86, up about 3.4% for the day, in a 52-week range of $11.37 to $19.09.

  • [By Garrett Baldwin]

    By submitting your email address you will receive a free subscription to Profit Alerts and occasional special offers from Money Map Press and our affiliates. You can unsubscribe at anytime and we encourage you to read more about our privacy policy.

    The Top Stock Market Stories for Tuesday
    Hedge fund manager Carl Icahn has reversed his position on a potential deal between Cigna Inc. (NYSE: CI) and Express Scripts Holding Co. (Nasdaq: ESRX). Icahn is no longer seeking votes against the $52 billion merger. Icahn had previously written a letter that argued Cigna was paying too much for the pharmacy-benefits manager. The turning point came after proxy advisories Glass Lewis & Co. and Institutional Shareholder Services Inc. both issued their public support for the deal. Hedge fund manager David Einhorn and his firm Greenlight Capital made a major announcement this morning. The fund has cut its stake in Apple Inc. (Nasdaq: AAPL), Twitter Inc. (NYSE: TWTR), and Micron Technology Inc. (Nasdaq: MU). The updates came in a filing to the U.S. Securities and Exchange Commission and stated his firm’s positions at the end of the second quarter.
    Three Stocks to Watch Today: HD, TSLA, KO
    Shares of Home Depot Inc. (NYSE: HD) are on the move after the home retail giant reported earnings before the bell. Home Depot said earnings per share came in at $3.05 on top of $30.46 billion in revenue. The average Wall Street estimate was $2.84 on top of $29.98 billion in revenue. The firm also hiked its full-year guidance. Shares of HD stock were up 2.2% in pre-market hours. Tesla Inc. (Nasdaq: TSLA) is dominating the news as CEO Elon Musk continues to push the narrative that he will be taking his company private. According to Reuters, Musk has been speaking with Saudi Arabian financiers and others about a deal to de-list Tesla. Meanwhile, Musk is facing a lawsuit from short sellers who claim that Musk’s recent announcement of his plan on Twitter last week was part of a broader

  • [By Paul Ausick]

    Canadian Solar Inc. (NASDAQ: CSIQ) saw an increase of 10.3% in short interest during the two weeks to June 29. Some 7.2% of the total float, or 3.23 million shares, were short, and days to cover rose from one to three. The company’s share price rose by 5.9% over the two-week period, and shares closed Wednesday at $13.02, down about 1.5% for the day, in a 52-week range of $11.37 to $19.09.

Top 5 Heal Care Stocks To Invest In 2019: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Keith Speights]

    AbbVie’s new hepatitis C virus (HCV) drug Mavyret appears to be giving Gilead Sciences (NASDAQ:GILD) a run for its money. In the first quarter, AbbVie’s net HCV revenue came in at $919 million. That total includes both of the company’s HCV drugs, Viekira and Mavyret. But there’s virtually no question that Mavyret is contributing most of AbbVie’s HCV revenue.

  • [By Keith Speights]

    But at least three of the biotechs singled out by the FDA deserve to be on another list — investors’ buy lists. Here’s why Celgene (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), and Jazz Pharmaceuticals (NASDAQ:JAZZ) look like great stock picks right now.

  • [By Dan Caplinger]

    The iShares biotech ETF has a structure that’s familiar to anyone who invests regularly in exchange-traded funds. The ETF tracks an index of nearly 200 biotech and pharmaceutical stocks, with roughly 80% of assets dedicated to true biotechs and the rest split evenly between pharma and life sciences equipment and services providers. Top ETF holdings Biogen (NASDAQ:BIIB), Amgen (NASDAQ:AMGN), and Gilead Sciences (NASDAQ:GILD) make up a total of roughly 25% of the fund’s assets.

  • [By Cory Renauer]

    AbbVie’s new hepatitis C virus (HCV) treatment is priced to compete with Gilead Sciences (NASDAQ:GILD) market-leading treatments and the strategy’s working. Mayvret has been a disaster for Gilead’s HCV franchise, but it did more to push AbbVie’s needle forward than any other product during the first quarter. AbbVie reported $919 billion in HCV antiviral sales, $656 million more than during the same period last year and $409 million more than during the previous quarter.

Top 5 Heal Care Stocks To Invest In 2019: CPS Technologies Corp.(CPSH)

Advisors’ Opinion:

  • [By Max Byerly]

    Media coverage about CPS Technologies (NASDAQ:CPSH) has been trending somewhat negative recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CPS Technologies earned a media sentiment score of -0.04 on Accern’s scale. Accern also gave news headlines about the electronics maker an impact score of 47.6937573591172 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Top 10 Warren Buffett Stocks For 2019

After a promising start to 2018, major stock indexes forfeited their yearly gains over the past few weeks amid heightened concerns about a looming trade war between the U.S. and China. Now, as investors look to rebound from what has been a tough stretch for many, it could prove prudent to dig deep into the tried-and-true strategies of Wall Street’s top figures.

One of those top performers is, of course, the legendary Warren Buffett. Dubbed the “Oracle of Omaha” for his decades of success, Buffett has amassed billions of dollars through a meticulous brand of value investing that touts patience and confidence. Simply put, Buffett and his Berkshire Hathaway (BRK.B ) firm are icons of the investing world.

Berkshire Hathaway’s U.S. long stock portfolio holds positions in 45 individual stocks, with the five-largest of those positions accounting for roughly 62% of its total value. This portfolio is tracked by a large swath of investors looking to mimic the success of Berkshire’s legendary CEO.

Top 10 Warren Buffett Stocks For 2019: Fibrocell Science Inc(FCSC)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Alexander Bird]

    We’re talking 471% potential gains…

    Penny Stock Current Share Price Last Week’s Gain
    Renren Inc. (NYSE: RENN) $2.50 158.64%
    Astrotech Corp. (Nasdaq: ASTC) $4.17 132.80%
    Xenetic Biosciences Inc. (Nasdaq: XBIO) $5.58 71.95%
    Nordic American Tanker Shipping Ltd. (NYSE: NAT) $2.73 38.43%
    United States Antimony Corp. (NYSE: UAMY) $0.49 36.47%
    Soeno Therapeutics Inc. (Nasdaq: SLNO) $2.65 33.05%
    Fibrocell Science Inc. (Nasdaq: FCSC) $3.16 31.36%
    Teekay Tankers Ltd. (NYSE: TNK) $1.30 29.70%
    Neovasc Inc. (Nasdaq: NVCN) $0.04 27.30%
    Actinium Pharmaceuticals Inc. (OTCMKTS: ATNM) $0.24 25.98%

    While the gains of last week’s top penny stocks are exciting, investors who know where to look can unlock even bigger gains…

  • [By Stephan Byrd]

    Here are some of the news articles that may have effected Accern’s rankings:

    Get Fibrocell alerts:

    Year-to-date (YTD) in the Spotlight Fibrocell Science, Inc. (NASDAQ:FCSC), eMagin Corporation (NYSE:EMAN … (stocksnewspoint.com) Have an eye on: Fibrocell Science, Inc. (NASDAQ:FCSC), Kelso Technologies Inc. (NYSE:KIQ), Siebert Financial Corp … (journalfinance.net) Fibrocell Science (FCSC) Sees Hammer Chart Pattern: Time to Buy? (finance.yahoo.com) Chester County gene therapy company completes $6M stock sale (finance.yahoo.com) Wining Three Stocks: MasTec, Inc. (NYSE:MTZ), Fibrocell Science, Inc. (NASDAQ:FCSC), Volt Information Sciences … (thestreetpoint.com)

    Shares of FCSC traded down $0.16 during mid-day trading on Friday, hitting $2.40. 283,121 shares of the company’s stock were exchanged, compared to its average volume of 206,910. The stock has a market capitalization of $14.57 million, a PE ratio of -0.29 and a beta of 0.45. Fibrocell has a fifty-two week low of $2.21 and a fifty-two week high of $23.20.

  • [By Lisa Levin]

    Shares of Fibrocell Science, Inc. (NASDAQ: FCSC) were down 10 percent to $2.58. Fibrocell reported a $6.0 million registered direct offering priced at-the-market.

Top 10 Warren Buffett Stocks For 2019: Coca-Cola Enterprises, Inc.(CCE)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Neuberger Berman Group LLC raised its holdings in Coca-Cola European Partners PLC (NYSE:CCE) by 35.5% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 31,270 shares of the company’s stock after acquiring an additional 8,187 shares during the quarter. Neuberger Berman Group LLC’s holdings in Coca-Cola European Partners were worth $1,326,000 at the end of the most recent quarter.

  • [By Logan Wallace]

    Aristotle Capital Management LLC raised its holdings in shares of Coca-Cola European Partners PLC (NYSE:CCE) by 9.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 363,371 shares of the company’s stock after purchasing an additional 30,783 shares during the period. Aristotle Capital Management LLC owned approximately 0.08% of Coca-Cola European Partners worth $15,138,000 at the end of the most recent quarter.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Coca-Cola European Partners (CCE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

    Get Coca-Cola European Partners alerts:

    Coca-Cola European Partners (CCE) Lowered to “Sell” at ValuEngine (americanbankingnews.com) $3.69 Billion in Sales Expected for Coca-Cola European Partners (CCE) This Quarter (americanbankingnews.com) Zacks: Analysts Anticipate Coca-Cola European Partners (CCE) to Post $0.81 EPS (americanbankingnews.com) Critical Contrast: Coca-Cola European Partners (CCE) and Coca-Cola Bottling Co. Consolidated (COKE) (americanbankingnews.com) Coca-Cola European Partners (CCE) Sees Large Drop in Short Interest (americanbankingnews.com)

    Shares of CCE traded down $0.51 during trading hours on Monday, hitting $37.88. The stock had a trading volume of 705,278 shares, compared to its average volume of 1,496,087. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $18.60 billion, a PE ratio of 15.85, a P/E/G ratio of 1.93 and a beta of 0.76. Coca-Cola European Partners has a 1-year low of $36.17 and a 1-year high of $44.75.

Top 10 Warren Buffett Stocks For 2019: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Reuben Gregg Brewer, Rich Smith, and Sean Williams]

    Not many companies have monopolies, though some get pretty close. That list includes Russian telecom giantMobile TeleSystems (NYSE:MBT), biotech playerGilead Sciences, Inc.(NASDAQ:GILD), and tobacco makerAltria Group, Inc. (NYSE:MO). Each one has a slightly different virtual monopoly and they clearly have vastly different businesses. But if you are looking for income from seriously entrenched industry players, you’ll want to get to know this trio of high-yielders.

  • [By Cory Renauer]

    AbbVie’s new hepatitis C virus (HCV) treatment is priced to compete withGilead Sciences (NASDAQ:GILD) market-leading treatments and the strategy’s working. Mayvret has been a disaster for Gilead’s HCV franchise, but it did more to push AbbVie’s needle forward than any other product during the first quarter. AbbVie reported $919 billion in HCV antiviral sales, $656 million more than during the same period last year and $409 million more than during the previous quarter.

  • [By Chris Lange]

    Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest increase to 18.14 million shares from 16.28 million in the previous period. Shares were trading at $71.83 in a 52-week range of $63.76 to $89.54.

  • [By Chris Lange]

    Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest increase slightly to 16.28 million shares from 16.13 million in the previous period. Shares were trading at $67.85, in a 52-week range of $63.76 to $89.54.

  • [By Keith Speights]

    But at least three of the biotechs singled out by the FDA deserve to be on another list — investors’ buy lists. Here’s why Celgene (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), and Jazz Pharmaceuticals (NASDAQ:JAZZ) look like great stock picks right now.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Gilead Sciences (GILD)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Warren Buffett Stocks For 2019: iShares Morningstar Large-Cap Growth (JKE)

Advisors’ Opinion:

  • [By Joseph Griffin]

    iShares Morningstar Large Growth (NYSEARCA:JKE) declared a quarterly dividend on Tuesday, June 26th, Wall Street Journal reports. Investors of record on Wednesday, June 27th will be paid a dividend of 0.3796 per share on Monday, July 2nd. This represents a $1.52 annualized dividend and a yield of 0.87%. The ex-dividend date is Tuesday, June 26th. This is a boost from iShares Morningstar Large Growth’s previous quarterly dividend of $0.34.

Top 10 Warren Buffett Stocks For 2019: Iridium Communications Inc(IRDM)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Ground-based wireless communications networks have transformed the way that billions of people across the globe communicate. For the locations where traditional wireless networks either haven’t yet reached or have decided aren’t feasible for ground-based stations, Iridium Communications (NASDAQ:IRDM) hopes that its extensive and growing satellite communications network will be the go-to solution for users who need reliable coverage under challenging circumstances.

  • [By Max Byerly]

    Iridium Communications (NASDAQ: IRDM) and Inseego (NASDAQ:INSG) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

  • [By Daniel Sparks]

    Shares of satellite communications company Iridium Communications(NASDAQ:IRDM) jumped as much as 16.4% on Friday,following the announcement of a partnership between Iridium and in-flight broadband connectivity and wireless entertainment services company Gogo(NASDAQ:GOGO). At the time of this writing, Iridium stock is up 11.3% on Friday.

  • [By Ethan Ryder]

    Iridium Communications (NASDAQ:IRDM) last announced its earnings results on Thursday, April 26th. The technology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.04 by $0.03. The business had revenue of $119.10 million during the quarter, compared to the consensus estimate of $111.60 million. Iridium Communications had a net margin of 44.81% and a return on equity of 5.19%. Iridium Communications’s revenue was up 14.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 EPS. sell-side analysts forecast that Iridium Communications Inc will post 0.11 EPS for the current year.

  • [By Nicholas Rossolillo]

    Shares of satellite communications provider Iridium Communications (NASDAQ:IRDM) rocketed 40% higher in the last two weeks. The company has had good press since its first-quarter 2018 report at the end of April, making advancements with its new network and getting some help from Wall Street analysts. While there was good reason to feel optimistic, expectations might need to be tempered after the stock pop.

Top 10 Warren Buffett Stocks For 2019: Euro Tech Holdings Company Limited(CLWT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Euro Tech Holdings Company Limited (NASDAQ: CLWT) was down, falling around 7 percent to $3.745 after dropping 30.26 percent on Friday.

    Commodities

  • [By Lisa Levin]

    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares shot up 35 percent to $5.20 after the company declared a $0.70 per share special dividend.

  • [By Lisa Levin]

    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares shot up 93 percent to $6.16 after reporting 2017 year-end results.

    Shares of SORL Auto Parts, Inc. (NASDAQ: SORL) got a boost, shooting up 13 percent to $5.90 after reporting upbeat Q1 results.

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) rose 18.2 percent to $4.55 in pre-market trading after the company declared a $0.70 per share special dividend.
    Co-Diagnostics, Inc. (NASDAQ: CODX) rose 11.7 percent to $3.24 in pre-market trading after falling 13.17 percent on Thursday. Co-Diagnostics reported its participation in a research project with the Stanford University.
    Abercrombie & Fitch Co. (NYSE: ANF) shares rose 8.6 percent to $25.95 in pre-market trading after the company posted upbeat Q1 results.
    Zuora, Inc. (NYSE: ZUO) shares rose 8 percent to $23.95 in pre-market trading after the company reported upbeat Q1 earnings and issued strong outlook.
    Lululemon Athletica Inc. (NASDAQ: LULU) shares rose 7.8 percent to $113.25 in pre-market trading after the company reported better-than-expected results for its first quarter. The company also raised its FY18 earnings and sales guidance.
    OPKO Health, Inc. (NYSE: OPK) rose 5.7 percent to $4.10 in pre-market trading.
    Lannett Company, Inc. (NYSE: LCI) rose 5.5 percent to $17.45 in pre-market trading following the FDA approval for Levofloxacin Oral Solution.
    Eversource Energy (NYSE: ES) shares rose 5 percent to $59.8 in pre-market trading.
    VMware, Inc. (NYSE: VMW) rose 4.6 percent to $143.74 in pre-market trading as the company reported stronger-than-expected results for its first quarter on Thursday.
    Energy Transfer Partners, L.P. (NYSE: ETP) rose 4.3 percent to $19.80 in pre-market trading after the company reported the Federal Energy Regulatory Commission approval to place Rover pipeline’s full Mainline B into service.
    T2 Biosystems, Inc. (NASDAQ: TTOO) rose 4.3 percent to $7.73 in pre-market trading after declining 4.26 percent on Thursday.
    Curis, Inc. (NASDAQ: CRIS) rose 4.3 percent to $2.90 in pre-market trading after jumping 21.93 percent on Thursday.
    Sasol Limited (NYSE: SSL) rose 4.2 percent to $37.91 in pre-market trading.
    Nucor Corporatio
  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Verastem, Inc. (NASDAQ: VSTM) fell 9.7 percent to $4.73 in pre-market trading after announcing a $35 million common stock offering.
    Evolus, Inc. (NASDAQ: EOLS) shares fell 8 percent to $13.48 in pre-market trading ahead of regulatory update at 8:30 a.m. ET.
    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) fell 6.5 percent to $2.01 in pre-market trading after climbing 10.50 percent on Tuesday.
    Purple Innovation, Inc. (NASDAQ: PRPL) shares fell 5.8 percent to $9.36 in pre-market trading after reporting Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) fell 5.7 percent to $5.15 in pre-market trading after declining 5.04 percent on Tuesday.
    RYB Education, Inc. (NYSE: RYB) shares fell 5 percent to $16.39 in pre-market trading following Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares fell 4.4 percent to $4.30 in pre-market trading after rising 40.62 percent on Tuesday.
    Arbor Realty Trust, Inc. (NYSE: ABR) fell 4.4 percent to $8.92 in pre-market trading after announcing a 5.5 million share common stock offering.
    Daxor Corporation (NYSE: DXR) fell 4.1 percent to $7.32 in pre-market trading.
    Ormat Technologies, Inc. (NYSE: ORA) shares fell 3.8 percent to $51.03 in pre-market trading after the company announced plans to restate its Q2, Q3, Q4 and FY 2017 financial statements.
    Canadian Solar Inc. (NASDAQ: CSIQ) fell 3.5 percent to $16.20 in pre-market trading after reporting Q1 results.
    CELYAD SA/ADR (NASDAQ: CYAD) shares fell 3.3 percent to $29.70 in pre-market trading after the company reported launch of 1.8 million share offering

  • [By Lisa Levin]

    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares shot up 40 percent to $5.3750 after the company declared a $0.70 per share special dividend.

Top 10 Warren Buffett Stocks For 2019: Beneficial Mutual Bancorp Inc.(BNCL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Media coverage about Beneficial Bancorp (NASDAQ:BNCL) has trended positive recently, according to Accern. Accern identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Beneficial Bancorp earned a news impact score of 0.38 on Accern’s scale. Accern also gave media headlines about the bank an impact score of 45.8699493506664 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

  • [By Ethan Ryder]

    BidaskClub upgraded shares of Beneficial Bancorp (NASDAQ:BNCL) from a sell rating to a hold rating in a report released on Tuesday morning.

    Shares of Beneficial Bancorp opened at $16.35 on Tuesday, MarketBeat.com reports. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $1.23 billion, a P/E ratio of 31.44 and a beta of 0.55. Beneficial Bancorp has a fifty-two week low of $14.40 and a fifty-two week high of $17.50.

  • [By Logan Wallace]

    Beneficial Bancorp (NASDAQ: BNCL) and Home Bancorp (NASDAQ:HBCP) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

  • [By Joseph Griffin]

    Beneficial Bancorp Inc (NASDAQ:BNCL) Director Thomas J. Lewis sold 973 shares of the company’s stock in a transaction dated Wednesday, May 30th. The stock was sold at an average price of $16.50, for a total value of $16,054.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Top 10 Warren Buffett Stocks For 2019: TrueBlue Inc.(TBI)

Advisors’ Opinion:

  • [By Stephan Byrd]

    American Century Companies Inc. grew its holdings in shares of Trueblue Inc (NYSE:TBI) by 24.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 95,307 shares of the business services provider’s stock after purchasing an additional 18,680 shares during the period. American Century Companies Inc. owned approximately 0.23% of Trueblue worth $2,468,000 as of its most recent SEC filing.

  • [By Logan Wallace]

    Trueblue (NYSE: TBI) is one of 23 public companies in the “Help supply services” industry, but how does it contrast to its rivals? We will compare Trueblue to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, earnings and risk.

  • [By Joseph Griffin]

    Trueblue Inc (NYSE:TBI) has received a consensus rating of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a hold recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $27.50.

  • [By Stephan Byrd]

    Russell Investments Group Ltd. grew its stake in Trueblue Inc (NYSE:TBI) by 21.2% during the first quarter, HoldingsChannel reports. The fund owned 137,178 shares of the business services provider’s stock after purchasing an additional 23,951 shares during the quarter. Russell Investments Group Ltd.’s holdings in Trueblue were worth $3,553,000 at the end of the most recent quarter.

Top 10 Warren Buffett Stocks For 2019: Hexcel Corporation(HXL)

Advisors’ Opinion:

  • [By Max Byerly]

    Earnest Partners LLC increased its position in Hexcel Co. (NYSE:HXL) by 2.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,810,533 shares of the aerospace company’s stock after buying an additional 54,698 shares during the quarter. Hexcel accounts for 1.7% of Earnest Partners LLC’s portfolio, making the stock its 3rd largest position. Earnest Partners LLC’s holdings in Hexcel were worth $181,532,000 at the end of the most recent quarter.

  • [By Ethan Ryder]

    Hexcel Co. (NYSE:HXL) has earned a consensus rating of “Hold” from the fourteen analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $71.27.

  • [By Logan Wallace]

    Xact Kapitalforvaltning AB lifted its position in shares of Hexcel Co. (NYSE:HXL) by 51.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,174 shares of the aerospace company’s stock after acquiring an additional 3,800 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Hexcel were worth $722,000 at the end of the most recent quarter.

  • [By Joseph Griffin]

    Trillium Asset Management LLC lessened its holdings in Hexcel (NYSE:HXL) by 12.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 331,664 shares of the aerospace company’s stock after selling 47,089 shares during the quarter. Hexcel makes up approximately 1.2% of Trillium Asset Management LLC’s investment portfolio, making the stock its 19th largest position. Trillium Asset Management LLC owned 0.37% of Hexcel worth $21,422,000 at the end of the most recent quarter.

  • [By Lee Samaha]

    Advanced materials are loosely defined as those designed with enhanced properties that improve on traditionally used materials. A broader definition includes materials seeing increased demand due to advanced technologies. For example, if you want to reduce the weight of aircraft (while also increasing strength) then Hexcel Corp. (NYSE: HXL) advanced composites are going to come in handy. Similarly, if you believe in the future of electric vehicles then the lithium produced byAlbemarle Corp. (NYSE: ALB) (used in batteries) will surely come into high demand in the future. Moreover, if you want to invest in companies that provide technology to materials processors then high-performance laser manufacturer IPG Photonics Corp. (NASDAQ: IPGP) is well worth a look. Here’s the investment case for all three.

Top 10 Warren Buffett Stocks For 2019: CLP Holdings Ltd (2)

Advisors’ Opinion:

  • [By ]

    (1) Cash flow adjusted by working capital and, in the case of Aramco, $21.4 billion owed to the company from the government (2) Production for all companies is the annual average for 2016, the most recent figures available for Aramco

  • [By ]

    Long-Short sub-strategy funds gained 1.24 percent in May, underperforming the S&P 500 by 117 basis points.

    NOTE: Go to HFND and select option 3 to see the Bloomberg Hedge Fund Database Snapshot for more details on hedge fund performanceNOTE: See HFS to screen for specific hedge fundsNOTE: All data are total return including reinvested dividends. May data are the most recent available. June returns become available around July 12.NOTE: “Equity Hedge” refers to a Bloomberg-created term for strategies where the largest subset of funds is L/S Equity and Long-Biased hedge fundsRELATED: Here are how some hedge funds performed last monthJune 11: Hedge Fund With 69% Return Sees More to Come From Oil RecoveryJune 8: Macro Hedge Funds Cashed In on Mess From Italy, Trade Wars (2)June 7: BlackRock’s Biggest Hedge Fund Bleeds Talent as Deputy CIOs Exit

    — With assistance by Brian Pennisi

Hot Undervalued Stocks To Own For 2019

Generating alpha in today’s market is quite challenging. With the speed that information is disseminated it has become difficult to find undervalued opportunities to achieve outsized returns; once news becomes public, a stock quickly is re-priced to reflect this new information. In today’s highly competitive environment, the way to beat the market is to put disparate pieces of information together to paint a picture of what might be coming down the pipe.

Prior Examples

Glu Mobile (GLUU) Example

My article on GLUU provides a good example of how I pieced together disparate pieces of information to generate alpha. In my article entitled Glu Mobile: A Stock Darling for 2017, I outlined several factors that were contributing to the stock trading at a significantly undervalued level. These factors included: tax loss harvesting, investors not pricing in the value of GLUU’s evergreen strategy, GLUU’s short interest level, and strong insider buying.

Each of these factors in isolation didn’t provide a compelling narrative as to GLUU’s potential, but by putting them all together one is able to see why the stock might be temporarily trading at a depressed level. At the time of publishing, GLUU was trading at $1.94 per share and I suggested investors take their profits in August at $3.15 per share–although this was a bit too early since the stock is currently trading at $5.76 per share. Nonetheless, this anecdote provides evidence about how it is still possible to do a deep dive on a company and glean insight into why the market may be myopically viewing a stock.

Hot Undervalued Stocks To Own For 2019: RAIT Financial Trust(RAS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    RAIT Financial Trust (NYSE:RAS) will announce its earnings results before the market opens on Wednesday, May 23rd. Analysts expect the company to announce earnings of $0.21 per share for the quarter.

Hot Undervalued Stocks To Own For 2019: 1st Source Corporation(SRCE)

Advisors’ Opinion:

  • [By ]

    Currently, I like People’s Utah Bancorp (Nasdaq: PUB), 1st Source Corporation (Nasdaq: SRCE), and East West Bancorp (Nasdaq: EWBC) as stocks likely to benefit in the small/regional sector.

  • [By Max Byerly]

    1st Source (NASDAQ:SRCE)’s share price hit a new 52-week high and low during mid-day trading on Thursday . The stock traded as low as $56.13 and last traded at $55.94, with a volume of 100 shares changing hands. The stock had previously closed at $55.94.

  • [By Max Byerly]

    1st Source Co. (NASDAQ:SRCE) has been assigned a consensus rating of “Hold” from the six analysts that are presently covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $55.00.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on 1st Source (SRCE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Undervalued Stocks To Own For 2019: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Logan Wallace]

    KBC Group NV trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 227,921 shares of the biopharmaceutical company’s stock after selling 27,406 shares during the period. KBC Group NV’s holdings in Gilead Sciences were worth $17,183,000 at the end of the most recent quarter.

  • [By Todd Campbell]

    Sangamo Therapeutics has alsoinked a collaborationwith Gilead Sciences (NASDAQ:GILD)to work on ZFN approaches that may improve cancer treatment. As part of that deal, Sangamo received an upfront payment of $150 million from Gilead Sciences and it could receive up to $3.01 billion in potential milestones. If any therapies from this collaboration win approval, then Sangamo will receive tiered royalties on future sales.

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB),Celgene Corporation (NASDAQ:CELG), andGilead Sciences Inc.(NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.

  • [By Matthew Cochrane]

    A value trap is a stock that appears to be cheap but, in reality, is not because of deteriorating business conditions. Examples of traps include pharmaceutical companies with a valuable patent set to expire, cyclical stocks at the peak of the cycle, or tech stocks in the midst of having their expertise being commoditized away. Unfortunately, this is a pitfall I have firsthand experience with. In early 2016, I bought shares of Gilead Sciences, Inc. (NASDAQ: GILD) for just under $93. At the time, Gilead’s trailing twelve months EPS was $11.74 giving it what I thought was a dirt cheap P/E ratio of 7.9 — I thought shares were a steal.

Hot Undervalued Stocks To Own For 2019: Student Transportation Inc(STB)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Student Transportation (STB)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By ]

    That was certainly the case with Student Transportation (NYSE: STB). My former High-Yield Investing holding was trading at $6.00 per share at the closing bell on February 27. The next morning, it opened near $7.50 following a surprise takeover offer from a privately held Canadian company — giving us a nice 25% gain overnight.

  • [By ]

    One of the main goals of my premium newsletter High-Yield Investing is stability. I like industries that don’t go through unpredictable hot and cold cycles. Student Transportation (NYSE: STB) is a textbook example.

Hot Undervalued Stocks To Own For 2019: CSP Inc.(CSPI)

Advisors’ Opinion:

  • [By Logan Wallace]

    Headlines about CSP (NASDAQ:CSPI) have been trending somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CSP earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave headlines about the information technology services provider an impact score of 44.9831568716707 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Atara Biotherapeutics: What Q1 2018 Earnings Foretell?

The big money is not in the buying and selling. But in the waiting. – Charlie Munger

Atara Biotherapeutics (NASDAQ:ATRA) is one of the most promising growers that weve encountered thus far. As follows, the company is hitting its growth inflection with a key late-stage T-cell immunotherapeutic (tab-cel, formerly known as ATA-129). In anticipating the strong data reporting, the company is preparing for launch in the EU by hiring more professionals and investing in logistics. That aside, this robust grower is deepening its research and development (R&D) into the highly lucrative, next-generation cancer treatment, chimeric antigen receptor and T-cell receptor (CAR-TCR or CAR-T). But thats not all. There is an extremely intriguing molecule in-development (ATA-188) that can shock the medical as well as investment community: it is likely the silver bullet for the highly difficult-to-manage autoimmune condition, multiple sclerosis. As reflective of the increasing intrinsic value, the stock has been on an uptrend for the past 52 weeks. Since our recommendation, the shares appreciated by $28.42 to trade at $42.75 for over 205% profits. In this research, well elucidate the latest earnings developments and catalysts that can catapult the shares to a new high.

Figure 1: Atara Biotherapeutics stock chart. (Source: StockCharts).

Fundamental Analysis

We wish to provide a brief background on Atara for new investors. Headquartered in South San Francisco, California, the company is focusing on the innovation allogenic T-cell immunotherapies (A-TCI) to service a vast number of cancers and autoimmune diseases (as depicted in figure 2). A-TCI functions quite similar to CAR-T: both therapeutics enlighten the key regulatory cells of the immune system (i.e., the T-cells which are analogous to the generals of an army). We noted in the prior research,

Ataras A-TCIs are differentiated from those of Kite Pharma (NASDAQ:KITE), a bioscience acquired by Gilead Sciences (NASDAQ:GILD). In specific, Ataras A-TCI primed the intelligence of CD8 (killer) T-cells to detect and destroy cancers. This is important, as killer T-cells are adept at attacking viruses (to kill virus-induced tumors). Of note, tab-cel is an off-the-shelf Epstein-Barr virus (EBV)-specific A-TCI. Accordingly, the FDA gave the firm the nod to initiate their two phase 3 trials (MATCH/ALLELE) for ATA-129 in patients with rituximab-refractory EBV associated PTLD. Moreover, the said molecule gained the orphan designation from both the FDA and the EMA. Furthermore, the agency designated the mentioned drug as a Breakthrough Therapy while the EMA put it in the Priority Medicines regulatory pathway. In addition, Health Canada placed it in the expedited approval category.

Figure 2: Therapeutic pipeline (Source: Atara).

Of the various developing events, we are most interested in the development regarding tab-cel. Interestingly, the clinical sites for the two phase 3 (MATCH and ALLELE) have opened in the US. And, sites elsewhere are expected to be available soon. In anticipation of the launch of tab-cel, the company pushed various programs. For instance, the hiring of Manuela Maronati signifies the anticipation of an EU approval (and for tab-cel to be initially commercialized in Europe). In addition, the recent partnership with TrakCel is certainly foretelling an upcoming launch. As the industry-leading software provider, TrakCel developed the logistics program coined Atara MatchMe. This is to improve the customer experience (to push for the most aggressive/prompt delivery of tab-cel to patients). Its important for investors to realize that a drug approval does not guarantee a launch success. Instead, prior preparations such as the hiring of experts and logistics planning (as what Atara accomplished) are crucial steps for the improved launch outcomes. Commenting on such developments, the President and CEO (Dr. Isaac Ciechanover) enthused,

During Q1 2018, we continued to advance our T-cell immunotherapy pipeline and platform. Our two phase 3 pivotal studies of tab-cel are progressing, and we remain focused on building Ataras global commercial and operational capabilities in anticipation of the first tab-cel Phase 3 results and submission of an EU conditional marketing authorization application in H1 2019. We are also excited to have recently expanded our collaboration with Memorial Sloan Kettering Cancer Center to develop next-generation CAR-T technologies, marking our entry into genetically engineered T-cells and furthering our leadership position in off-the-shelf, A-TCI. I am pleased with our strong operational and strategic execution in Q1 and look forward to both continuing this momentum and updating you on our progress throughout the rest of the year.

Aside from the upcoming tab-cel launch, were highly excited about the recent MSK-partnership to deepen the research and development (R&D) for tapping into the highly lucrative field (CAR-T) that we discussed in the prior research. Along with this catalyst, the company inked an extensive partnership with MSKs think-tank, Dr. Michel Sadelain. This contract secured the top-notch intelligence for the innovation of a novel CAR-T construct that is both gene-edited and off-the-shelf. We elucidated,

On May 08, 2018, Atara announced the expansion of its collaboration with MSK for the innovation of the next-generation CAR-T. As alluded, Ataras A-TCI functions quite similar to that of CAR-T. What is unique is that A-TCI – and CAR-T – are off-the-shelf: this confers the rapid commercialization as well offers patients convenience. As a ramification, the agreement extended the original collaboration between Atara and MSK – in the hopes to deliver stellar medicines that have the potential to transform the lives of patients afflicted by life-threatening malignancies. Pertaining to the deal specificity, Atara will have access to MSKs key biotechnologies (including a novel CAR-T construct). The said technology would enable Atara to design physiologic T-cell activation properties.

For Q1 2018 (ended on March 31), Atara reported $41.4M ($1.05 per share) in net losses compared to $28.5M ($0.88 per share) decline for the same period a year prior. The higher losses were due to the increasing R&D, which is prudent for a company advancing its therapeutic development. Investors should be cognizant that it is the norm for a relatively young bioscience like Atara to incur significant losses for many years prior to banking a net profit (due to the lengthy and low success rate of the innovation process). Nonetheless, it only takes one blockbuster to make your investment worthwhile. Regarding the balance sheet, there was $407.3M, thereby representing the 39% improvement versus the $293.3M for Q1. Based on these metrics, there should be adequate cash to fund operations into mid-2020 (prior to any additional financing).

Final Remarks

Atara is brewing two stellar analogous platforms (A-TCI and CAR-T). There are numerous catalysts powering this superb grower. One, the advancement of tab-cell development and the corporate preparation for the EU launch are signaling that the company is at its growth inflection: this is a point in the companys growth cycle where the stock can trade aggressively higher. The deepened relationship with MSK for the novel CAR-T development – to service cancer, autoimmune as well as infectious diseases – added significant value to the pipeline. Additionally, the increased cash position via the public offering to gear up for launch and to expand its R&D is highly strategic. Despite the highly favorable chances of positive outcomes for MATCH and ALLELE, there is roughly a small chance of a negative clinical binary. In that case, its most likely that the shares will depreciate over 80%, and vice versa.

Authors Notes: Were honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (IBI) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 320%, 160%, 242%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advance and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I like to inform our readers of Seeking Alpha’s recent policy change, in which the company implemented the paywall (not only to my articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.

Hot Low Price Stocks To Invest In 2019

A few days ago, an article about Nike (NYSE:NKE) argued that “Nike’s shares aren’t priced to buy.” The reasoning was that “Nike is, at best, fairly valued. And it certainly isn’t trading hands at fire-sale prices.” The question is: should you expect (and wait for) fire-sales prices? Most value investors know the maxim that it is better to buy a great business at a fair price than to buy a mediocre business at low price. We think that Nike is a great business at a fair price. We have been waiting for Nike’s price to come down for a long time and meanwhile, we have sold PUT options, though unfortunately these options have never been exercised (but we cashed-in premiums). Today, we bought the stock.

Reasons to avoid the stock

We invest with a long-term view and therefore we ask long-term questions:

Has the management of Nike changed its strategy? Is Nike’s long-term strategy ultimately going to fail? Is there anything that can or has damaged the Nike brand?

Of course, competition is there, but is there any industry where there is no long-term competition? Under Armour (NYSE:UAA), Adidas (OTCQX:ADDDF), Lululemon (NASDAQ:LULU) are all good companies, but they have always been there. Under Armour and Lululemon are perceived as new entrants, but they were actually founded 20 years ago (in 1996 and 1998), Adidas is almost a century old, while Nike is “only” 52-years old. So, what has changed? These industries move in waves, but the quality of the Nike brand, its management, and innovation have been a constant. In sum, if your answer to any of the previous questions is YES, then you should reconsider our investment thesis. If it is NO, then we can move on to the next paragraph.

Hot Low Price Stocks To Invest In 2019: Agenus Inc.(AGEN)

Advisors’ Opinion:

  • [By Max Byerly]

    Agenus (NASDAQ:AGEN) shares traded up 5.6% during mid-day trading on Thursday . The stock traded as high as $3.44 and last traded at $3.60. 39,070 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,431,827 shares. The stock had previously closed at $3.41.

  • [By Shane Hupp]

    Shares of Agenus (NASDAQ:AGEN) dropped 9.8% during trading on Monday following a dissappointing earnings announcement. The stock traded as low as $3.30 and last traded at $3.32. Approximately 2,421,286 shares changed hands during mid-day trading, an increase of 53% from the average daily volume of 1,586,724 shares. The stock had previously closed at $3.68.

  • [By Cory Renauer]

    Attention bargain shoppers: There could be some deals in aisle biotech.Agenus Inc.(NASDAQ:AGEN)andRegeneron Pharmaceuticals (NASDAQ:REGN) dished out some disappointing losses in recent months, but the market’s reaction to recent events seems a bit overdone.

  • [By Cory Renauer]

    Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical trials.

Hot Low Price Stocks To Invest In 2019: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By George Budwell]

    Bellicum is attempting to bring a safer and more potent form of adoptive cell therapy to market for a variety of cancers and orphan inherited blood disorders. By doing so, the company hopes to overcome the extensive leads currently held by the FDA-approved therapies ofGilead Sciences (NASDAQ:GILD) — via its acquisition of Kite Pharma, and Novartis (NYSE:NVS).

  • [By ]

    What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.

  • [By Todd Campbell, Sean Williams, and Brian Feroldi]

    There’s no telling if the data will be good, but if it is, Galapagos could benefit significantly from milestone payments and royalties. For instance, its lead product, filgotinib, is licensed to biotech Goliath Gilead Sciences(NASDAQ:GILD) and is being evaluated in a variety of blockbuster autoimmune indications. Results from a phase 3 rheumatoid arthritis study should be available in the second half of 2018; since that market is worth more than $16 billion per year, the payoff for investors could be big. Galapagos will share in EU profits on filgotinib, plus it can collect 20% to 30% royalties on U.S. sales if filgotinibeventually wins an OK.

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB),Celgene Corporation (NASDAQ:CELG), andGilead Sciences Inc.(NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.

Hot Low Price Stocks To Invest In 2019: Farmer Brothers Company(FARM)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Farmer Brothers (FARM)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Low Price Stocks To Invest In 2019: Enerplus Corporation(ERF)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Enerplus (NYSE:ERF) (TSE:ERF) – Stock analysts at National Bank Financial reduced their FY2018 earnings estimates for Enerplus in a research note issued on Thursday, May 3rd. National Bank Financial analyst T. Wood now forecasts that the oil and natural gas company will earn $1.13 per share for the year, down from their previous estimate of $1.27. National Bank Financial also issued estimates for Enerplus’ FY2019 earnings at $1.96 EPS.

Hot Low Price Stocks To Invest In 2019: KBR, Inc.(KBR)

Advisors’ Opinion:

  • [By ]

    KBR (NYSE: KBR)
    Though an under-the-radar name, KBR was the construction arm of oilfield services giant Halliburton (NYSE: HAL) before being spun off. With a consolidated market cap of $2.6 billion, KBR describes itself, per its website, as a “global provider of differentiated professional services and technologies within the Government Services and Hydrocarbon sectors.”

Top Casino Stocks To Own Right Now

Related 4/20 Is Here: These Are The 15 Most Traded Weed Stocks 15 Marijuana Stocks To Watch In 2015: Where Are They Now?
Related AAPL A Preview Of An Important Upcoming Event: The William Blair Growth Stock Conference Here's Why Tech Stocks Fell Today Stocks Mostly Lower for the Week (GuruFocus)

American Green Inc (OTC: ERBB) recently unveiled a new system that allows vending machines to sell controlled and age-restricted products like alcohol, pharmaceuticals, casino chips, cannabis and even firearms. The system uses state-of-the-art biometric verification technology to ensure each user can legally make the desired transaction.

Top Casino Stocks To Own Right Now: Skyworks Solutions, Inc.(SWKS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Skyworks Solutions (SWKS) soared to the top of the S&P 500 today after beating first-quarter earnings forecasts, and offering above-consensus second-quarter guidance.

    Getty Images

    Skyworks Solutions gained 13% to $88.67, while the S&P 500 rose 0.3% to 2,271.31.

    Oppenheimer’s Rick Schafer and team argue that Skyworks’ “growth [is] back on track.” They explain:

    We expect Skyworks to deliver above-market growth driven by 1) continued smartphone content gains; 2) China share gains through strengthening baseband partnerships and demand for integrated (vs. discrete) RF solutions; 3) seasonal uptick at Samsung; and 4) continued double-digit RF complexity increases. With its “one-stop-shop” systems-level approach, we seeSkyworks uniquely positioned to benefit from rising RF content. We reiterate Outperform and raise PT to $105 from $100.

    Skyworks Solutions’ market capitalization rose to $16.5 billion today from $14.6 billion yesterday.

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Lisa Levin]

    Shares of Skyworks Solutions Inc (NASDAQ: SWKS) got a boost, shooting up 12 percent to $87.70 after the company reported upbeat results for its first quarter and issued a strong outlook for the second quarter. The company also announced a $500 million buyback plan.

  • [By Garrett Baldwin]

    That’s especially the case for a semiconductor firms like Skyworks Solutions Inc. (Nasdaq: SWKS), which has heavy exposure in China. In 2015, 67% of Skyworks’ revenue alone came from The Red Dragon.

Top Casino Stocks To Own Right Now: Gilead Sciences, Inc.(GILD)

Advisors’ Opinion:

  • [By Ben Levisohn]

    JPMorgan is hosting its health care conference this week, which has provided opportunities for companies to provide updates on their pipelines, profits and even M&A plans before a captive audience. And of course, Gilead Sciences (GILD) was there, and its management spoke to analysts about its business, including the possibility for…M&A, which we don’t need to remind you is much on investors’ minds. Mizuho’s Salim Syed offered his takeaway on the subject:

  • [By Laurie Kulikowski]

    The company’s current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, GILEAD SCIENCES INC’s return on equity significantly exceeds that of both the industry average and the S&P 500.

     

  • [By Chris Lange]

    Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest decrease slightly to 15.55 million shares from 15.68 million in the previous period. Shares closed Friday at $75.44, in a 52-week trading range of $71.39 to $108.31.

  • [By Sean Williams]

    Though drugmaker Gilead Sciences (NASDAQ:GILD) has lost 25% over the trailing-12-month period, underperforming the S&P 500 by 41 percentage points, I believe now would be the perfect time for income investors to give it a closer look.

Top Casino Stocks To Own Right Now: Canfor Corporation (CFPZF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Conifex has been shoring up its balance sheet over the last year, taking advantage of its strong financial performance. Beginning in February 2016, Conifex announced it was settling a $30m convertible debt it had with Canfor (OTCPK:CFPZF) in exchange for a forest license it held that permitted an allowable annual cut of 200,000 cubic meters. In April 2016, it created a joint venture for another one of its forest licenses, which netted it another $20m.

Top Casino Stocks To Own Right Now: Glaukos Corporation(GKOS)

Advisors’ Opinion:

  • [By Nelson Hem]

    In "Skeptics Eye Potential Trouble for Glaukos," Vito J. Racanelli suggests that, even though Glaukos Corp (NYSE: GKOS) has warned that it might lose money this year, Wall Street appears to be betting otherwise. This eye-stent maker has had success with a breakthrough product and dominates its market, but formidable competition still looms.

Top Casino Stocks To Own Right Now: Ono Pharmaceutical Co., Ltd. (OPHLF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Merck could achieve a consistent advantage versus BMS in treatment of 1L NSCLC. There is a precise crossroad that will determine the future of these two companies in this field: the question of whether or not Keytruda will be approved in May. Both the market and investors believe that it will indeed gain approval and BMS’s stock is already paying for that. In the short term, the repercussions will be the contractions in the sales of Opdivo in 2L and a bigger obstacle for Opdivo+Yervoy in 1L. But the BMS’s combo can catch up, thanks to a bigger efficacy, as I will explain in a future article. Meanwhile, a recent trial established that Merck has to pay BMS $625M plus royalties, as it infringed BMS’s intellectual property related to the use of anti-PD1 antibodies. The royalties will be 6.5% for sales between January 2017 and the end of 2023, followed by a 2.5% rate for the period from January 2024 to the end of 2026. Bristol-Myers Squibb will share the money by giving a quarter of the amount to the Japanese Ono Pharmaceutical (OTC:OPHLF), the company which had discovered Opdivo.

Top Casino Stocks To Own Right Now: DigitalGlobe, Inc(DGI)

Advisors’ Opinion:

  • [By Ethan Ryder]

    COPYRIGHT VIOLATION WARNING: “DigitalGlobe (DGI) Earning Somewhat Positive Press Coverage, Report Shows” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at www.tickerreport.com/banking-finance/3360325/digitalglobe-dgi-earning-somewhat-positive-press-coverage-report-shows.html.

  • [By Scott Rubin]

    Stock gainers included DigitalGlobe (NYSE: DGI), which jumped almost 17 percent on a strong earnings report, and B&G Foods, Inc.(NYSE: BGS) which added 13 percent after its Q2 report. Shares of Western Digital (NASDAQ: WDC) lost more than 11 percent after its quarterly earnings results disappointed Wall Street.

  • [By Lisa Levin]

    In trading on Wednesday, telecommunications services shares rose by just 0.03 percent. Meanwhile, top losers in the sector included Internet Initiative Japan Inc. (ADR) (NASDAQ: IIJI), down 4 percent, and DigitalGlobe Inc (NYSE: DGI), down 2 percent.